Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the issues in human health caused by biofilms in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for postoperative wound; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Stock data | 2024 | Change |
---|---|---|
Price | $0.15295197308045275 | N/A |
Market Cap | $44.62M | N/A |
Shares Outstanding | 291.70M | N/A |
Employees | 0 | N/A |